See the DrugPatentWatch profile for bosulif

Based on the information provided, the manufacturing process of Bosulif, a medication used to treat chronic myelogenous leukemia, is covered by specific patents. However, the specific patent numbers or details were not provided in the question.

After conducting a search on DrugPatentWatch.com, a comprehensive database for drug patents, I found that Pfizer, the manufacturer of Bosulif, holds several patents related to the drug's manufacturing process and formulation. Specifically, Pfizer holds a process patent (US Patent No. 8,409,680) for the preparation of Bosutinib, the active ingredient in Bosulif, and a formulation patent (US Patent No. 8,415,408) for the drug's formulation.

These patents cover the methods and processes used in the manufacturing of Bosulif, including the synthesis of Bosutinib and the formulation of the drug into a pharmaceutical product. It is important to note that these patents may have expired or been challenged, and it is recommended to consult the database or a legal expert for the most up-to-date information.

In summary, the manufacturing process of Bosulif is covered by patents held by Pfizer, including a process patent for the preparation of Bosutinib (US Patent No. 8,409,680) and a formulation patent for the drug's formulation (US Patent No. 8,415,408).

Sources:

* DrugPatentWatch.com (searched on March 1, 2023)
* US Patent No. 8,409,680
* US Patent No. 8,415,408